Idorsia Ltd
SIX:IDIA
Idorsia Ltd
Revenue
Idorsia Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Idorsia Ltd
SIX:IDIA
|
Revenue
CHf97.1m
|
CAGR 3-Years
60%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Revenue
$69.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
129%
|
CAGR 10-Years
N/A
|
|
AC Immune SA
NASDAQ:ACIU
|
Revenue
CHf14.8m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Revenue
$371.2m
|
CAGR 3-Years
709%
|
CAGR 5-Years
160%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Revenue
CHf157.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
14%
|
|
Kuros Biosciences AG
SIX:KURN
|
Revenue
CHf33.6m
|
CAGR 3-Years
103%
|
CAGR 5-Years
116%
|
CAGR 10-Years
N/A
|
See Also
What is Idorsia Ltd's Revenue?
Revenue
97.1m
CHF
Based on the financial report for Dec 31, 2022, Idorsia Ltd's Revenue amounts to 97.1m CHF.
What is Idorsia Ltd's Revenue growth rate?
Revenue CAGR 5Y
-9%
Over the last year, the Revenue growth was 175%. The average annual Revenue growth rates for Idorsia Ltd have been 60% over the past three years , -9% over the past five years .